Drug‐eluting versus third‐generation bare metal stents: The US strategy

References

• Thompson C. A., Kaplan A. V., Jayne J. E., et al. Impact and temporal trends of percutaneous coronary intervention in the drug‐eluting stent versus bare metal stent eras. Am J Cardiol 2005; 96: 668–72
   PubMedGoogle Scholar
• Morice M. ‐C., Serruys P. W., Sousa J. E., et al. A randomized comparison of a sirolimus‐eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773–80
   PubMed Web of Science ®Google Scholar
• Park S., Shim W. H., Ho D. S., et al. A paclitaxel‐eluting stent for the prevention of coronary restenosis. N Engl J Med 2003; 348: 1537–45
   PubMed Web of Science ®Google Scholar
• Moses J. W., Leon M. B., Popma J. J., et al. Sirolimus‐eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315–23
   PubMed Web of Science ®Google Scholar
• Stone G. W., Ellis S. G., Cox D. A., et al. A polymer‐based, paclitaxel‐eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221–31
   PubMed Web of Science ®Google Scholar
• Ardissino D., Cavallini C., Bramucci E., et al. Sirolimus‐eluting vs uncoated stents for prevention of restenosis in small coronary arteries. JAMA 2004; 292: 2727–34
   PubMed Web of Science ®Google Scholar
• Schofer J., Schluter M., Gershlick A. H., et al. Sirolimus‐eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double‐blind, randomized controlled trial (E‐SIRIUS). Lancet 2003; 362: 1093–9
   PubMed Web of Science ®Google Scholar
• Leon M. B., Mehran R., Popma J., et al. Long‐term results after sirolimus‐eluting stent in small vessel lesions: an integrated analysis of six multicenter trials (abstract). J Am Coll Cardiol 2005; 45(Suppl A)84A
   Google Scholar
• Kastrati A., Mehilli J., von Becherath N., et al. Sirolimus‐eluting stent or paclitaxel‐eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in‐stent restenosis. JAMA 2005; 293: 165–71
   PubMed Web of Science ®Google Scholar
• Vermeersch P., Van Langenhove G., Convens C., et al. First randomized trial comparing sirolimus‐eluting stents versus bare metal stents in severely diseased saphenous vein graft treatment: six month clinical and angiographic outcome (abstract). J Am Coll Cardiol 2005; 45(Suppl A)84A
   Google Scholar
• Serruys P. W., for the ARTS‐II investigators. ARTS‐II: Arterial Revascularization Therapies Study Part II of the sirolimus‐eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. Late Breaking Clinical Trial. Presented at: the American College of Cardiology 54th Annual Meeting, Orlando, Florida, March, 2005
   Google Scholar
• Lotan C., Gershlick A., Guagliumi G., et al. Treatment of chronic total occlusion with the sirolimus‐eluting stent – results from the e‐Cypher Registry (abstract). J Am Coll Cardiol 2005; 45(Suppl A)47A
   Google Scholar
• Nakamura S., Muthusamy T. S., Bae J. H., et al. Comparison of efficacy and safety between sirolimus‐eluting stent (Cypher) and paclitaxel‐eluting stent (TAXUS) on the outcomes ofpatients withchronic total occlusions: Multicenter Registry in Asia (abstr). J Am Coll Cardiol 2005; 45(Suppl A)47A
   Google Scholar
• Park S. J., Kim Y. H., Lee B. K., et al. Sirolimus‐eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. J Am Coll Cardiol 2005; 45: 351–6
   PubMed Web of Science ®Google Scholar
• Colombo A., Moses J. W., Morice M. C., et al. Randomized study to evaluate sirolimus‐eluting stents implanted at coronary bifurcation lesions. Circulation 2004; 109: 1244–9
   PubMed Web of Science ®Google Scholar
• Cohen D. J., Bakhai A., Shi C., et al. Cost‐effectiveness of sirolimus‐eluting stents for treatment of complex coronary stenoses. Circulation 2004; 110: 508–14
   PubMed Web of Science ®Google Scholar
• Wokhlu A., Jollis J. G. Dollars and stents: the economics of drug‐eluting stents. Am Heart Hosp J 2005; 3: 94–8
   PubMedGoogle Scholar
• Hodgson J. M., King S. B., Feldman T., Cowley M. J., Klein L. W., Babb J. D. SCAI statement on drug‐eluting stents: Practice and health care delivery implications. Cath Cardiovasc Interv 2003; 58: 397–9
   PubMed Web of Science ®Google Scholar
• Kaiser C., Brunner‐La Rocca H. P., Buser P. T., et al. Incremental cost‐effectiveness of drug‐eluting stents compared with a third‐generation bare‐metal stent in a real‐world setting: randomized Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005; 366: 921–9
   PubMed Web of Science ®Google Scholar
• Iakovou I., Schmidt T., Bonizzoni E., et al. JAMA 2005; 293: 2126–30
   PubMed Web of Science ®Google Scholar
• Ge L., Lakovou I., Tsagalou E., et al. Thrombosis after drug‐eluting stent implantation inbifurcation lesions by crush stent technique (abstract). J Am Coll Cardiol 2005; 45(Suppl A)65A
   PubMedGoogle Scholar
• Van der Hoeven B. L., Pires N. M. M., Warda H. M., et al. Drug‐eluting stents: results, promises and problems. Intl J Cardiol 2005; 99: 9–17
   PubMed Web of Science ®Google Scholar
• Morice M. C., for the REALITY investigators. REALITY: A prospective, randomized, multi‐center comparison study of the Cu[jer sirolimus‐eluting and Taxus paclitaxel‐eluting stent systems. Late Breaking Clinical Trial presented at: the American College of Cardiology 54th Annual Meeting, Orlando, Florida, March, 2005
   Google Scholar
• Windecker S., Remondino A., Eberli F. R., et al. Sirolimus‐eluting and paclitaxel‐eluting stents for coronary revascularization. N Engl J Med 2005; 353: 653–62
   PubMed Web of Science ®Google Scholar
• Dibra A., Kastrati A., Mehilli J., et al. Paclitaxel‐eluting or sirolimus‐eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663–70
   PubMed Web of Science ®Google Scholar
• Kastrati A., Mehilli J., Dirschinger J., et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR‐STEREO) trial. Circulation 2001; 103: 2816–21
   PubMed Web of Science ®Google Scholar
• Pache J., Kastrati A., Mehilli J., et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR‐STEREO‐2) trial. J Am Coll Cardiol 2003; 41: 1283–8
   PubMed Web of Science ®Google Scholar
• Briguori C., Sarais C., Pagnotta P., et al. In‐stent restenosis in small coronary arteries: impact of strut thickness. J Am Coll Cardiol 2002; 40: 403–9
   PubMed Web of Science ®Google Scholar
• Pache J., Dibra A., Mehilli J., Dirschinger J., Schomig A., Kastrati A. Drug‐eluting stents compared with thin‐strut bare stents for the reduction of restenosis: a prospective, randomized trial. European Heart Journal 2005; 26: 1262–8
   PubMed Web of Science ®Google Scholar
• Sketch M. H., Ball M., Rutherford B., Popma J. J., Russell C., Kereiakes D. J. Evaluation of the Medtronic (Driver) cobalt‐chromium alloy coronary stent system. Am J Cardiol 2005; 95: 8–12
   PubMed Web of Science ®Google Scholar
• Kereiakes D. J., Cox D. A., Hermiller J. B., et al. Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol 2003; 92: 463–6
   PubMed Web of Science ®Google Scholar
• Wijns W., Fajadet J., Kuntz R. E. A randomized comparison of the Endeavor ABT‐576 drug eluting stent with a bare metal stent for coronary revascularization: results of the ENDEAVOR‐II Trial. Late Breaking Clinical Trial. Presented at: the American College of Cardiology 54th Annual Meeting, Orlando, Florida, March, 2005
   Google Scholar
• Hermiller J. B., Raizner A., Cannon L., et al. Outcomes with the polymer‐based paclitaxel‐eluting TAXUS stent in patients with diabetes mellitus. J Am Coll Cardiol 2005; 45: 1172–9
   PubMed Web of Science ®Google Scholar